Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation

Oncotarget

Volumn 6, Issue 12, 2015, Pages 9854-9876

  Wang, Neng ^a   Wang, Zhiyu ^a,b   Wang, Yu ^c   Xie, Xiaoming ^d   Shen, Jiangang ^a   Peng, Cheng ^e   You, Jieshu ^a   Peng, Fu ^a   Tang, Hailin ^d   Guan, Xinyuan ^c   Chen, Jianping ^a,e  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cancer stem cells; DNMT1; Isoliquiritigenin; Mammary tumorigenesis; WIF1 demethylation

Indexed keywords

BETA CATENIN; DNA METHYLTRANSFERASE 1; ISOLIQUIRITIGENIN; UNCLASSIFIED DRUG; WNT INHIBITORY FACTOR 1; WNT PROTEIN; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; SCLEROPROTEIN; SIGNAL PEPTIDE; SMALL INTERFERING RNA; WIF1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CANCER STEM CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMETHYLATION; DOWN REGULATION; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LUNG METASTASIS; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; CHEMISTRY; CYTOLOGY; DIETARY SUPPLEMENT; DNA METHYLATION; DRUG EFFECTS; ENZYME ACTIVE SITE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELL LINE; METABOLISM; METASTASIS; SECONDARY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTICARCINOGENIC AGENTS; BETA CATENIN; BREAST NEOPLASMS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CHALCONES; DIETARY SUPPLEMENTS; DNA METHYLATION; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; MICE, TRANSGENIC; MOLECULAR DOCKING SIMULATION; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84929590467     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3396     Document Type: Article

References (79)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100:3983-3988.
3. Subramaniam D, Ramalingam S, Houchen CW, Anant S. Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev Med Chem. 2010; 10:359-371.
4. Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis:cancer stem cells in metastasis. Cell Res. 2007; 17:3-14.
5. Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget. 2010; 1:552-566.
6. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982; 31:99-109.
7. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene. 2000; 19:1002-1009.
8. Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 1994; 54:2615-2621.
9. Polakis P. Wnt signaling and cancer. Genes Dev. 2000; 14:1837-1851.
10. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010; 176:2911-2920.
11. Su Y, Fu C, Ishikawa S, Stella A, Kojima M, Shitoh K, Schreiber EM, Day BW, Liu B. APC is essential for targeting phosphorylated β-catenin to the SCFβ-TrCP ubiquitin ligase. Mol Cell. 2008; 32:652-661.
12. He JP, Hao Y, Wang XL, Yang XJ, Shao JF, Guo FJ, Feng JX. Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev. 2014; 15:5967-5976.
13. Wang N, Wang ZY, Peng C, You JS, Shen JG, Han SW, Chen JP. Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling. Carcinogenesis. 2014; 35:2544-2554.
14. Kawano Y. J Cell Sci. 2003; 116:2627-2634.
15. Suzuki M, Shigematsu H, Nakajima T, Kubo R, Motohashi S, Sekine Y, Shibuya K, Iizasa T, Hiroshima K, Nakatani Y, Gazdar AF, Fujisawa T. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res. 2007; 13:6087-6092.
16. Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis. 2006; 27:1341-1348.
17. Veeck J, Wild PJ, Fuchs T, Schuffler PJ, Hartmann A, Knuchel R, Dahl E. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer. 2009; 9:217.
18. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013; 13:11-26.
19. Landis-Piwowar KR, Iyer NR. Cancer chemoprevention:current state of the art. Cancer Growth Metastasis. 2014; 7:19-25.
20. Li Y, Wicha MS, Schwartz SJ, Sun D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem. 2011; 22:799-806.
21. Park CH, Chang JY, Hahm ER, Park S, Kim HK, Yang CH. Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun. 2005; 328:227-234.
22. Kim J, Zhang X, Rieger-Christ KM, Summerhayes IC, Wazer DE, Paulson KE, Yee AS. Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J Biol Chem. 2006; 281:10865-10875.
23. Lee YM, Jeong GS, Lim HD, An RB, Kim YC, Kim EC. Isoliquiritigenin 2′-methyl ether induces growth inhibition and apoptosis in oral cancer cells via heme oxygenase-1. Toxicol In Vitro. 2010; 24:776-782.
24. Park I, Park KK, Park JH, Chung WY. Isoliquiritigenin induces G2 and M phase arrest by inducing DNA damage and by inhibiting the metaphase/anaphase transition. Cancer Lett. 2009; 277:174-181.
25. Wang ZY, Wang N, Han SW, Wang D, Mo S, Yu L, Huang H, Tsui K, Shen JG, Chen JP. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLoS One. 2013; 8:e68566.
26. Kwon GT, Cho HJ, Chung WY, Park KK, Moon A, Park JH. Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. J Nutr Biochem. 2009; 20:663-676.
27. Chen G, Hu X, Zhang W, Xu N, Wang FQ, Jia J, WF, Sun ZJ, Zhao YF. Mammalian target of rapamycin regulates isoliquiritigenin-induced autophagic and apoptotic cell death in adenoid cystic carcinoma cells. Apoptosis. 2012; 17:90-101.
28. Lau GT, Ye L, Leung LK. The licorice flavonoid isoliquiritigenin suppresses phorbol ester-induced cyclooxygenase-2 expression in the non-tumorigenic MCF-10A breast cell line. Planta Med. 2010; 76:780-785.
29. Cuendet M, Guo J, Luo Y, Chen S, Oteham CP, Moon RC, van Breemen RB, Marler LE, Pezzuto JM. Cancer chemopreventive activity and metabolism of isoliquiritigenin, a compound found in licorice. Cancer Prev Res (Phila). 2010; 3:221-232.
30. Wang C, Schwab LP, Fan M, Seagroves TN, Buolamwini JK. Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer. Cancer Prev Res (Phila). 2013; 6:437-447.
31. Franci C, Zhou J, Jiang Z, Modrusan Z, Good Z, Jackson E, Kouros-Mehr H. Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTVPyMT breast cancer model. PLoS One. 2013; 8:e58183.
32. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003; 163:2113-2126.
33. Tu SM. Cancer: a "stem-cell" disease? Cancer Cell Int. 2013; 13:40.
34. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1:555-567.
35. Liu J, Lam JB, Chow KH, Xu A, Lam KS, Moon RT, Wang Y. Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis. 2008; 29:2195-2202.
36. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64:52-62.
37. Weinberg RA. How cancer arises. Sci Am. 1996; 275:62-70.
38. Lori J, Sharad G, Paul F, Jeffrey W, Melanie R, Shari BG. Breast Cancer Overview: Risk Factors, Screening, Genetic Testing, and Prevention. Cancer Management. 2014.
39. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin. 2004; 54:150-180.
40. Amin AR, Kucuk O, Khuri FR, Shin DM. Perspectives for cancer prevention with natural compounds. J Clin Oncol. 2009; 27:2712-2725.
41. Kelloff G. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res. 2000; 78:199-334.
42. Crowell JA. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview". Eur J Cancer. 2005; 41:1889-1910.
43. Cazzaniga M, Bonanni B. Breast cancer chemoprevention:old and new approaches. J Biomed Biotechnol. 2012; 0:98562.
44. den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol. 2013; 3:250.
45. El-Bayoumy K, Chung FL, Richie JJr, Reddy BS, Cohen L, Weisburger J, Wynder EL. Dietary control of cancer. Proc Soc Exp Biol Med. 1997; 216:211-223.
46. Yang CS, Feng Q. Chemo/Dietary prevention of cancer:perspectives in China. J Biomed Res. 2014; 28:447-455.
47. Yamamoto S, Aizu E, Jiang H, Nakadate T, Kiyoto I, Wang JC, Kato R. The potent anti-tumor-promoting agent isoliquiritigenin. Carcinogenesis. 1991; 12:317-323.
48. Baba M, Asano R, Takigami I, Takahashi T, Ohmura M, Okada Y, Sugimoto H, Arika T, Nishino H, Okuyama T. Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol Pharm Bull. 2002; 25:247-250.
49. Pogribny IP. Epigenetic events in tumorigenesis: putting the pieces together. Exp Oncol. 2010; 32:132-136.
50. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis:epigenetics joins genetics". Trends Genet. 2000; 16:168-174.
51. Tang Y, Simoneau AR, Liao WX, Yi G, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, Mercola D, Hoang BH, Zi X. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells". Mol Cancer Ther. 2009; 8:458-468.
52. Rubin EM, Guo Y, Tu K, Xie J, Zi X, Hoang BH. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther. 2010; 9:731-741.
53. Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook DM, Zuna R, Lightfoot S, Reis A, Anant S, Queimado L. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene. 2012; 31:2725-2737.
54. Weiss AJ, Stambaugh JE, Mastrangelo MJ, Laucius JF, Bellet RE. Phase I study of 5-azacytidine (NSC-102816). Cancer Chemother Rep. 1972; 56:413-419.
55. Weiss AJ, Metter GE, Nealon TF, Keanan JP, Ramirez G, Swaiminathan A, Fletcher WS, Moss SE, Manthei RW. Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep. 1977; 61:55-58.
56. Vesely J, Cihak A. Possibilities for the clinical use of 5-azacytidine. Vopr Onkol. 1977; 23:65-73.
57. Saiki JH, McCredie KB, Vietti TJ, Hewlett JS, Morrison FS, Costanzi JJ, Stuckey WJ, Whitecar J, Hoogstraten B. 5-azacytidine in acute leukemia. Cancer. 1978; 42:2111-2114.
58. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer". Anticancer Drugs. 1997; 8:358-368.
59. Baba M, Asano R, Takigami I, Takahashi T, Ohmura M, Okada Y, Sugimoto H, Arika T, Nishino H, Okuyama T. Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol Pharm Bull. 2002; 25:247-250.
60. Joska TM, Zaman R. Belden WJ. Regulated DNA methylation and the circadian clock: implications in cancer. Biology (Basel). 2014; 3:560-577.
61. Cheng X, Blumenthal RM. Mammalian DNA methyltransferases:a structural perspective. Structure. 2008; 16:341-350.
62. Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, Li PK, Lin J, Fuchs JR, Marcucci G, Li C, Chan KK. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett. 2009; 19:706-709.
63. Yu J, Peng Y, Wu LC, Xie Z, Deng Y, Hughes T, He S, Mo X, Chiu M, Wang QE, He X, Liu S, Grever MR, Chan KK, Liu Z. Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. PLoS One. 2013; 8:e55934.
64. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer. 2005; 41:2438-2448.
65. Wang XB, Peng WQ, Yi ZJ, Zhu SL, Gan QH. Expression and prognostic value of transcriptional factor sp1 in breast cancer. Ai Zheng. 2007; 26:996-1000.
66. Zannetti A1, Del Vecchio S, Romanelli A, Scala S, Saviano M, Cali' G, Stoppelli MP, Pedone C, Salvatore M. Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells. Biochem Pharmacol. 2005; 70:1277-1287.
67. Maor S, Papa MZ, Yarden RI, Friedman E, Lerenthal Y, Lee SW, Mayer D, Werner H. Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1. Horm Metab Res. 2007; 39:179-185.
68. Chang WC, Hung JJ. Functional role of post-translational modifications of Sp1 in tumorigenesis. J Biomed Sci. 2012; 19:94.
69. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst. 2005; 97:1498-1506.
70. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002; 21:5483-5495.
71. Pan MH, Chiou YS, Chen LH, Ho CT. Breast cancer chemoprevention by dietary natural phenolic compounds:specific epigenetic-related molecular targets. Mol Nutr Food Res. 2014; doi: 10.1002/mnfr.201400515.
72. Chikan NA, Bhavaniprasad V, Anbarasu K, Shabir N, Patel TN. From natural products to drugs for epimutation computer-aided drug design". Appl Biochem Biotechnol. 2013; 170:164-175.
73. Yoo J, Kim JH, Robertson KD, Medina-Franco JL. Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNMT1 inhibitor. Adv Protein Chem Struct Biol. 2012; 87:219-247.
74. Nagy T, Wei H, Shen TL, Peng X, Liang CC, Gan B, Guan JL. Mammary epithelial-specific deletion of the focal adhesion kinase gene leads to severe lobulo-alveolar hypoplasia and secretory immaturity of the murine mammary gland. J Biol Chem. 2007; 282:31766-31776.
75. Lohberger B, Rinner B, Stuendl N, Absenger M, Liegl-Atzwanger B, Walzer SM, Windhager R, Leithner A. Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PLoS One. 2012; 7:e43664.
76. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18:1427-1431.
77. Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004; 64:4717-4720.
78. Yang Z, Wang Y, Fang J, Chen F, Liu J, Wu J, Song T, Zeng F, Rao Y. Downregulation of WIF-1 by hypermethylation in astrocytomas. Acta Biochim Biophys Sin. 2010; 42:418-425.
79. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics. 2005; 21:4067-4068.